Gilead’s Q2 sales excluding Veklury rose 10%, with HIV sales up 12%; Medtronic posted 13.7% organic growth in Q1 FY2027, partly boosted by an extra fiscal week. Gilead has faster underlying growth; Medtronic is more diversified and has a 49-year dividend-growth record.
Gilead’s Q2 product sales excluding Veklury totaled $7.6 billion, with HIV contributing $5.69 billion—about three-quarters of the total. The company raised its 2026 product-sales guidance to $30.1 billion-$30.4 billion and its quarterly dividend to $0.82, effective in 2026. It also recorded $11.2 billion in acquired in-process R&D expenses, primarily tied to Arcellx, Tubulis and Ouro Medicines; the acquisitions contributed to GAAP and non-GAAP losses per share of $8.45 and $6.75, respectively.
Medtronic reported $9.76 billion in Q1 FY2027 revenue, with organic growth of 18.9% in Cardiovascular, 9.3% in Neuroscience and 10.2% in Medical Surgical. It raised FY2027 organic revenue-growth guidance to 7.25%-7.75% and lifted the lower end of its non-GAAP EPS guidance, with the range at $5.94-$6.00. In FY2026, non-GAAP EPS grew 0.7% to $5.53 and operating margin fell 130 basis points; Q1 FY2027 EPS then rose 15.1% to $1.45, with margin up 10 basis points to 23.7%.
